Kidney-Targeted Drug Delivery Systems
AssigneeUniversity of Mississippi Medical Center
InventorsAlejandro R. Chade, III, Gene L. Bidwell, III
Life of this patent
Estimating the term…
Abstract
A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and. a therapeutic agent is provided. A method of delivering a therapeutic agent to a subject in need thereof comprising: administering to the subject an effective amount of a composition comprising: an elastin-like polypeptide (ELP), a kidney targeting agent coupled to the ELP and a targeting agent and/or a drug binding domain coupled to the ELP, wherein the ELP includes an amino acid sequence having at least about repeats of the amino acid sequence GVPGX (SEQ ID NO: 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.
Claims30
A method of delivering a therapeutic agent to a subject in need thereof, comprising:
- administering to the subject an effective amount of a composition comprising:
- an elastin-like polypeptide (ELP),
- a kidney targeting agent coupled to the ELP, and
- a therapeutic agent and/or a drug binding domain coupled to the ELP,
- wherein the ELP includes an amino acid sequence having at least about 5 repeats of the amino acid sequence GVPGX (SEQ ID NO:
- 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.
A method of treating a kidney disease in a subject, comprising:
- administering to the subject an effective amount of a composition comprising:
- an elastin-like polypeptide (ELP),
- a kidney targeting agent coupled to the ELP, and
- a therapeutic agent and/or a drug binding domain coupled to the ELP,
- wherein the ELP includes an amino acid sequence having at least about 5 repeats of the amino acid sequence GVPGX (SEQ ID NO:
- 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.
A composition, comprising:
- an elastin-like polypeptide (ELP),
- a kidney targeting agent coupled to the ELP,
- a therapeutic agent and/or a drug binding domain coupled to the ELP, and
- wherein the ELP includes an amino acid sequence having at least about 5 repeats of the amino acid sequence GVPGX (SEQ ID NO:
- 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.
Any method, system, compound and/or composition provided in the present disclosure.
Dependencies are inferred from the claim text.